introduction
India is the most populous democracy in the world. It was highlighted for a separate report by virtue of its vast population and political structure that grants individual states the authority to determine regional regulations for opioid prescribing and dispensing. The population of India is young. In 2010, more than 550 000 deaths caused by cancer (this is probably a major underestimate) were reported, mainly in persons 30-69 years of age. (including cancers of the lip, pharynx and tongue), which can produce severe cancer pain syndromes, and accounts for almost a quarter of all cancers in India [1] .
India grows opium in the three Northern states of Uttar Pradesh, Madhya Pradesh, and Rajasthan, and it exports the raw materials used to manufacture opioid analgesics around the world. Paradoxically, very little is produced for local medical use, and India has had very low opioid consumption [2] . While the global opioid consumption of opioids has increased throughout the last 30 years, there has been little increase in opioid consumption in India including morphine consumption (Figure 1 ), despite increasing economic and health care development throughout the country. When compared with other countries in the region, India's total opioid consumption is lower than most of its neighbors ( Figure 2 ).
The availability of opioids for the management of cancer pain has been severely curtailed by issues related to supply and distribution that arose as a consequence of the 1985 Narcotic Drugs and Psychotropic Substances Act, (NDPS). Under this law, the cultivation of poppy, collection of opium, and manufacture of morphine are controlled by the central government; the state governments control the sale and distribution of morphine. The law was passed in order to stop trafficking and abuse of drugs. As a consequence, it severely reduced the medical supply of morphine. Despite the discretionary authority of the states to liberalize rules regarding sale and distribution of morphine, up until 2008 only about 13 states in India and 1 union territory have simplified regulations. (India has 28 states and 7 union territories). Thirteen states had modified the rules to improve patient access to morphine; however, in most states, morphine consumption did not improve [2] . The state of Kerala led the way easing regulatory restrictions and by making palliative care available in every part of the state. Consequently, the state of Kerala hosts more than 75% of India's palliative care centers.
The impact of the NDPS is illustrated in a survey of 100 cancer patients treated in a tertiary hospital in the state of Uttarakhand [3] . Ninety-five percent of patients reported substantial pain, 66% received inadequate analgesics and only 6.32% received strong opioids. Impaired access to opioids has a major impact on the quality of life of patients. This is despite a 1990 study in Bangalore that showed in 223 patients that 'intractable cancer pain' could be successfully reduced in all of 17 patients with an average oral morphine dose of 196 mg/day [4] .
The catastrophic human consequences of the general unavailability of morphine or other strong pain medication for cancer patients has been highlighted in a detailed report by Human Rights Watch entitled Unbearable Pain: India's Obligation to Ensure Palliative Care [5] .
Hitherto there has been no detailed mapping of the different regulatory barriers encountered across the range of Indian states.
methodology
See Cherny et al. [6] .
results
Data are reported on the availability and accessibility of opioids for the management of cancer pain in 24 of the states that make up India and the Administrative area around Delhi. These data are relevant to 1061 million of the region's 1189 million people (89%). The Northeast states refer collectively to the seven states in the North East of India.
formulary availability and cost of opioids for cancer pain
The availability of opioids and their cost to consumers are summarized in Figure 3 and show many similarities throughout the country. Immediate release oral morphine is available throughout all states of India covered by this survey. Codeine, controlled release morphine and injectable morphine are available in most states. Transdermal (TD) fentanyl is available in all but two states. Oxycodone is only available in Kerala and West Bengal. Goa, Bihar and Odisha have only three of the seven essential medicines available. Greater than 50% of the cost of most medications is borne by patients. For injectable morphine, oxycodone and TD fentanyl, full cost are borne by the patient.
While reporters state that these medications were on formulary, only codeine is always or usually available. All other opioids, including oral morphine, are available occasionally, with one state Jharkhand, never having availability ( Figure 4 ).
regulatory restrictions to accessibility
These are detailed below and summarised in Table 12 . The Indian States overall have significant regulatory restrictions that limit accessibility of opioids.
requirement for permission/registration of a patient to render them eligible to receive an opioid prescription
In general, eligibility within a state was the same for outpatients, inpatients and hospice patients in almost all jurisdictions. Approximately half the states require special authorizations across all settings. Jharkhand required special authorizations for outpatients but not for inpatients and hospices ( Figure 5 ).
requirement for physicians and other clinicians to receive a special authority/license to prescribe opioids Across all states, there was little restriction on prescribing of opioids by oncologists or surgeons ( Figure 6 ). In most states, primary care physicians require a special authorization to prescribe opioids, and in four states (Bihar, Haryana, Punjab and Tamil Nadu), they could only prescribe opioids in emergency situations. Only the Delhi region allowed prescription by nurses or pharmacists in emergency situations.
requirement for duplicate prescriptions and special prescription forms
Fifteen of the 25 states and regions require duplicate or triplicate prescriptions ( Figure 7 ). When special forms were required, they were generally available except in Jharkhand and Kerala. In Kerala, physicians need to purchase the prescription forms.
prescription limits
Generally the maximum number of allowed days for the supply of opioids was 30 days (Figure 8 ). The maximum limitations on dispensing privileges
In most states opioids are dispensed only in hospital pharmacies ( Figure 9 ). Hospital pharmacies were the usual place except in Figure 4 . three states (Goa, Kerala and West Bengal) where any pharmacy was allowed to dispense opioids. In many states, patient accessibility to the sites of opioid dispensing are reported to be very limited. Pharmacists were not able to accept emergency scripts by fax or telephone and only in four states they were authorized to correct technical errors.
provision for opioid prescribing in emergency situations
An emergency situation is defined as one when there is an immediate need to relieve strong cancer pain but the physician is not able to physically provide a prescription. Examples include a pain crisis at night, on a public holiday or in a remote region. With the single exception of Gujurat, pharmacists were not able to accept emergency scripts by fax or telephone (Figure 10 ). The Delhi Region permitted non-medical prescribing by a pharmacist or nurse in an emergency situation ( Figure 6 ).
pharmacist privileges to correct a technical error on a prescription
In the situation of a patient presenting with a prescription that contains a technical error (no address, misspelling, missing value etc), a pharmacist was allowed to correct this in only of 4 of 25 regions (Delhi, Haryana, Punjab and Tripura) (Fig 10  last column) .
use of stigmatizing terminology for opioid analgesics in regulations
Indian law does not use stigmatizing negative language regarding opioids and restrictions on driving are made on a case-by-case basis in all states ( Figure 11 ) except Kerala where it is prohibited by patients taking opioids, irrespective of the cognitive or attentive function.
discussion
Cancer continues to be an increasing problem throughout the world with an increase in cancer incidence in low-and middleincome countries. Many adult patients in India present with advanced disease [1] as do many children with cancer who present late in the course of their disease [7] .
India's opioid consumption is among the lowest in the region ( Figure 2 ) and has been documented in various formats [8] [9] [10] . While many countries have shown an increase in consumption research article Annals of Oncology since 2000, India has very low and 'concerning' consumption as defined by the INCB with a S-defined daily dose (DDD) of <200 mg/day/100 000 people [8] . Indian data including S-DDD per capita and Adequacy of Consumption Measure (ACM) for opioids is compared with neighboring countries in Table 1 .
The approach to improving opioid consumption is guided by the WHO policy guidelines Ensuring Balance in National Policies on Controlled Substances, Guidance for availability and accessibility of controlled medicines [11] . Moreover, the WHO Palliative Care Strategy states that medication availabilty, education, and government policy must all be addressed and implemented if adequate pain relief and palliative care are to be provided.
medication availability
The access to opioids in India is limited to codeine and morphine. Only a few states had accessibility to oxycodone, methadone and fentanyl, but the quantities of morphine consumed continue to be very small. In 2008, India used an amount of morphine that was sufficient to adequately treat only about 40 000 of the estimated 1 million patients suffering from moderate to severe pain due to advanced cancer, about 4% of those needing it [5] .
The very low cost of immediate release morphine is itself a barrier to it accessibility. Because of its low cost, profit margins on morphine for both pharmaceutical companies and pharmacies are small, giving the latter little incentive to stock the medication-particularly, considering the extremely complex procedures for procuring it through Indian Licensing rules between states and the Federal Government [5] .
education
Much work needs to be done in educating clinicians in India on the role of opioids in cancer pain. After decades of strict regulation, the medical professionals developed a fear of morphine; many doctors are reluctant to use it and students have been taught to avoid it. Additionally, the general public, including government officials, associates morphine with inevitable dependency and are reluctant to accept the its use for medical needs [2] .
The Medical Council of India has approved a postgraduate course in palliative care, but the lack of teaching at the undergraduate level has seen few physicians develop careers in of palliative care [5] . Only a very small number of medical colleges in India have incorporated instruction on palliative care in the course materials for community health and on pain management for anesthesiology trainees. Some states still have no trained providers in palliative care.
Consumer education is critically important since many people commonly associate morphine with dependency disorder and substance abuse, and/or, with use to relive pain in the immenently dying [2] .
government policies and regulations
Until the early 1980s, the increase in morphine consumption in India was consistent with increases observed in the rest of the world. However, the enactment of the Narcotic Drugs and Psychotropic Substances (NDPS) Act saw a sudden and significant reduction in opioid consumption. This very complex set of procurement regulations discourages pharmacies and hospitals from stocking it, and health care workers from prescribing it. Consequently, over the next decade, consumption [12] . Two major policy factors contributed to this lack of balance: first, there was a 10-year mandatory minimum prison term for violations involving narcotic drugs in the 1985 Act. This led to pharmacies all over the country dropping morphine from their stock, rather than risk penalties. The states adopted complex narcotic drug rules following the 1985 Act [12] , requiring 'import, export and transport licenses to ship any amount of morphine between any two states, as if they were countries.' This resulted in cumbersome processes in making morphine available around the country.
The Federal government brought about changes in 1998 introducing the 'model rule' which permitted states to simplify their opioid regulations. It simplified the licensing and authorized the state Drugs Controller to 'recognize' medical institutions and allow them to possess morphine and to designate at least one qualified medical practitioner to prescribe morphine, ensure adequate stock, future needs, and maintain records and security. Despite this initiative many states still operate under outdated rules that severely impede availability of morphine. This is true for most states apart from Kerala which consumes 30% of the country's opioids while only having 2.5% of its population [5] .
A 'public interest litigation' was filed by the Indian Association of Palliative Care in 2007, pleading for access for morphine to patients in pain in the country. As a consequence of that application, the Indian Supreme Court ruled that all states must provide morphine at no cost to its residents. Failure to comply with the ruling requires that the state will have to send its Chief Secretary to appear before the Supreme Court.
In 2013, efforts are underway to bring about Federal control of opioid laws. These efforts are ongoing through a major revision of the NDPS Act, which is currently being addressed. The bill incorporates major changes that include the following: 1) Ensuring that a patient using narcotic drugs or psychotropic substances as medicine is not considered a substance abuser. 2) Enabling the Central government to ensure proactively the availability of narcotic drugs and psychotropic substances for medical and scientific use. 3) Transfer to the Federal from the State government the power to permit and regulate the possession, transport, interstate import, sale, purchase, consumption or use of medicinal opium and opioid medications. 4) Simplifying the process of licensing for import, export and transport of opioids.
conclusion
Opioid availability continues to be critically low throughout most of India. There is urgent need for the progress to be made in the slow process of regulatory reform to bring about improved access to opioids, essential medicines for the relief of suffering. 
